BioXcel Therapeutics, Inc. Class Action Lawsuit - BTAI

The filed complaint alleges that BioXcel Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company lacked adequate internal controls over protocol adherence and data integrity; (2) as a result, the Company’s principal investigator failed to adhere to the informed consent form approved by the Institutional Review Board; (3) the Company’s principal investigator failed to maintain adequate case histories for certain patients whose records were reviewed by the FDA; (4) the Company’s principal investigator fabricated email correspondence with a pharmacovigilance safety vendor that was then provided to the FDA; (5) the foregoing would negatively impact the Company’s ability to obtain regulatory approval of BXCL501 for the treatment of agitation associated with dementia in patients with probable Alzheimer’s disease; and (6) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

In order to be eligible to join the BTAI class action lawsuit, you must have incurred a loss on shares of BioXcel purchased during the class period listed above.

If you suffered a loss in BioXcel during the relevant time frame or pursuant to the relevant offering(s), you have until September 5, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.